Literature DB >> 31728711

Successful treatment of non-HIV progressive multifocal leukoencephalopathy: case report and literature review.

Mai Hamaguchi1, Keisuke Suzuki2, Hiroaki Fujita1, Takeo Uzuka3, Hadzki Matsuda3, Yukiko Shishido-Hara4, Satoko Arai5, Toshiki Nakamura6, Shigeru Kikuchi3, Kazuo Nakamichi7, Masayuki Saijo7, Koichi Hirata1.   

Abstract

BACKGROUND: Progressive multifocal leukoencephalopathy (PML) is a subacute onset demyelinating disease caused by JC virus and characterized by multifocal involvement of the subcortical white matter and cerebellar hemispheres or peduncles on magnetic resonance imaging (MRI). However, non-HIV PML patients with brain lesions limited to the cerebellum and brainstem have not been well characterized.
METHODS: We report a 68-year-old man with systemic lupus erythematosus under treatment with immunosuppressants who developed non-HIV PML with brain lesions limited to the cerebellum and brainstem and successfully treated with a combination of mefloquine and mirtazapine. We performed a literature review to characterize patients with non-HIV PML with brain lesions limited to the cerebellum and brainstem.
RESULTS: Eight cases with non-HIV brainstem/cerebellar form PML were identified including our case. All cases had compromised status related underlying diseases. Four (50%) had a good prognosis. Five cases were treated, including 3 with favourable outcomes. Between the good prognosis group (n = 4) and the poor prognosis group (n = 4), treatment status for PML and the interval between the initial manifestation and diagnosis did not differ. Among those who performed contrast-enhanced brain imaging, lesion enhancement was related to good prognosis (good prognosis group vs. poor prognosis group; 100% vs. 0%).
CONCLUSION: PML should be considered in the differential diagnosis of brain lesions limited to the cerebellum and brainstem in immunocompromised patients. The presence of immune response against JC virus and inflammatory reactions may indicate good prognosis in non-HIV brainstem/cerebellar form PML.

Entities:  

Keywords:  Cerebellum and brainstem; Mefloquine; Mirtazapine; Progressive multifocal leukoencephalopathy; Systemic lupus erythematosus

Mesh:

Substances:

Year:  2019        PMID: 31728711     DOI: 10.1007/s00415-019-09629-x

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   6.682


  37 in total

Review 1.  Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis.

Authors:  Chen S Tan; Igor J Koralnik
Journal:  Lancet Neurol       Date:  2010-04       Impact factor: 44.182

Review 2.  Central nervous system infectious diseases mimicking multiple sclerosis: recognizing distinguishable features using MRI.

Authors:  Antônio José da Rocha; Ingrid Aguiar Littig; Renato Hoffmann Nunes; Charles Peter Tilbery
Journal:  Arq Neuropsiquiatr       Date:  2013-09       Impact factor: 1.420

3.  Progressive multifocal leukoencephalopathy.

Authors:  B R Brooks; D L Walker
Journal:  Neurol Clin       Date:  1984-05       Impact factor: 3.806

4.  Cerebellar form of progressive multifocal leukoencephalopathy (PML).

Authors:  J Parr; D S Horoupian; A C Winkelman
Journal:  Can J Neurol Sci       Date:  1979-05       Impact factor: 2.104

5.  Mefloquine improved progressive multifocal leukoencephalopathy in a patient with systemic lupus erythematosus.

Authors:  Minako Beppu; Michi Kawamoto; Souichi Nukuzuma; Nobuo Kohara
Journal:  Intern Med       Date:  2012-05-15       Impact factor: 1.271

Review 6.  A review of the pharmacological and clinical profile of mirtazapine.

Authors:  S A Anttila; E V Leinonen
Journal:  CNS Drug Rev       Date:  2001

7.  Long-term remission in progressive multifocal leukoencephalopathy caused by idiopathic CD4+ T lymphocytopenia: a case report.

Authors:  M A Rueger; H Miletic; K Dorries; C Wyen; C Eggers; M Deckert; G Faetkenheuer; A H Jacobs
Journal:  Clin Infect Dis       Date:  2006-02-13       Impact factor: 9.079

8.  Predictive factors for prolonged survival in acquired immunodeficiency syndrome-associated progressive multifocal leukoencephalopathy.

Authors:  J R Berger; R M Levy; D Flomenhoft; M Dobbs
Journal:  Ann Neurol       Date:  1998-09       Impact factor: 10.422

9.  [Ineffective mefloquine therapy in progressive multifocal leukoencephalopathy complicated with malignant lymphoma: finding and usefulness of susceptibility-weighted imaging].

Authors:  Aya Morimoto; Hiroki Ueno; Hiroki Fujii; Takeshi Nakamura; Kazuo Nakamichi; Masayuki Saijo; Motohiro Yukitake; Masayasu Matsumoto
Journal:  Rinsho Shinkeigaku       Date:  2013

10.  Characteristics of progressive multifocal leukoencephalopathy clarified through internet-assisted laboratory surveillance in Japan.

Authors:  Kazuo Nakamichi; Hidehiro Mizusawa; Masahito Yamada; Shuji Kishida; Yoshiharu Miura; Toshio Shimokawa; Tomohiko Takasaki; Chang-Kweng Lim; Ichiro Kurane; Masayuki Saijo
Journal:  BMC Neurol       Date:  2012-10-15       Impact factor: 2.474

View more
  1 in total

1.  Oleate-induced aggregation of LC3 at the trans-Golgi network is linked to a protein trafficking blockade.

Authors:  Allan Sauvat; Guido Kroemer; Giulia Cerrato; Marion Leduc; Kevin Müller; Peng Liu; Liwei Zhao; Juliette Humeau; Wei Xie; Shuai Zhang; Oliver Kepp
Journal:  Cell Death Differ       Date:  2020-12-17       Impact factor: 15.828

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.